| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1096: Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis |
|
Medicine details |
|
| Medicine name | benralizumab (Fasenra®) |
| Formulation | solution for injection |
| Reference number | 5267 |
| Indication | Treatment of adults with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA), receiving oral corticosteroids with or without stable immunosuppressive therapy |
| Company | AstraZeneca UK Ltd |
| BNF chapter | Nutrition & blood |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 01/08/25 |
| NICE guidance | |